M alignant gliomas are the most common primary intracranial neoplasms. 1 More than 80% of tumors demonstrate local recurrence within 2 years after standard therapy consisting of surgery, radiation, and chemotherapy. 2 Preclinical studies and clinical trials with viral gene therapy have been implemented that are designed to provide the delivery of cytotoxic genes or proteins to glioma tissue. [3] [4] [5] [6] Advantages of adenovirus (Ad)-mediated gene therapy for gliomas include local, therapeutic gene transfer by stable, nonreplicating viruses containing genes that are not incorporated into the host genome. 7, 8 Some glioma cell lines, however, have decreased adenoviral fiber receptor expression. 9 Reduced receptor-mediated binding of Ad vectors to certain tumor cells and tissues has been reported to result in decreased transduction efficiencies. 10 In an effort to overcome this limitation, transfections with higher viral titers have been attempted in animal tumor models. 11 The enhanced host cellular and humoral immune responses induced by greater viral doses have resulted in transient expression of the delivered gene and precluded readministration of the same vector. 11, 12 To improve the gene delivery efficiency to different malignant glioma cell lines, an Ad vector (AdZ.F(pK7)) with a C-terminal modification of the fiber-coat protein encoding polylysine was designed to direct binding to heparan sulfate and polyanionic cellular receptors. 9, 13 AdZ.F(pK7) has been reported to increase the transduction of certain cell types, such as macrophages, endothelium, smooth muscle, and glioblastoma, which express low levels of native Ad fiber receptors. 13 An alternative approach to improving transduction in glioma cells is to enhance the binding of the Ad coat protein fiber to secondary integrin receptors, thereby mediating Ad internalization. 14 An Ad vector with a C-terminal addition of an arg-gly-asp (RGD) motif to fiber protein (AdZ.F(RGD)) was designed to mediate binding to ␣ integrin receptors. These integrin receptors can be cultured on endothelial and smooth muscle cells or can be up-regulated in vivo in response to multiple factors. 14, 15 We hypothesized that the fiber-coat protein modification would improve the viral transduction of therapeutic genes in glioma cells that lack fiber receptor expression.
To determine whether the transduction efficiency could be improved by use of these vectors expressing the ␤-galactosidase (␤-gal) reporter gene, we studied unmodified Ad vector, AdZ, compared with AdZ.F(pK7) and AdZ.F(RGD) in human (D54, U87) and rodent (C6, GL261) malignant glioma cell lines in vitro and in vivo. AdZ.F(pK7) increased the transduction efficiency in three malignant glioma cell lines in culture compared with AdZ. Injection of AdZ.F(pK7) in glioma tumors resulted in increased ␤-gal expression in all glioma models, and AdZ.F(RGD) increased expression in one glioma model compared with AdZ. These modified vectors demonstrate the feasibility of using Ad gene therapy to improve gene transfer efficiency by targeting glioma cell-specific receptors.
MATERIALS AND METHODS

Cell lines
Human glioblastoma multiform cells, U87 (American Type Culture Collection (ATCC), Manassas, Va), were grown in minimal essential medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal calf sera (FCS) (Intergen, Purchase, NY), 5% nonessential amino acids (Life Technologies), 5% sodium pyruvate, and 1% penicillin/streptomycin. Human anaplastic astrocytoma cells, D54 (University of Alabama Laboratories, Birmingham, Ala), and murine malignant glioma cells, GL261 (ATCC), were cultured in 50% Dulbecco's modified Eagle's medium with 50% F-12 medium (Life Technologies), 7% FCS (Intergen), and 1% penicillin/streptomycin. Rat malignant glioma cells, C6 (ATCC), were grown in F-10 medium (Life Technologies), 15% FCS (Intergen), 2.5% horse sera (Intergen), and 1% penicillin/streptomycin. Human alveolar epithelial cells, A549 (ATCC), were grown in low glucose Dulbecco's modified Eagle's medium (Life Technologies), 10% FCS (Intergen), and 1% penicillin/streptomycin. All cell lines were incubated as monolayers in culture at 37°C in 7% CO 2 .
Recombinant adenoviral vectors expressing the ␤-gal gene All adenoviral vectors were recombined with a replicationdeficient Ad type 5 containing the ␤-gal gene down stream of the cytomegalovirus promoter (GenVec, Rockville, Md). Construction of the adenoviral vector with the polylysine modification of the fiber protein, AdZ.F(pK7), 9, 13 of the adenoviral vector with the modification of the integrin receptor binding motif (RGD), AdZ.F(RGD), 9 and of the wild-type (wt) attenuated adenoviral vector, AdZ, 7, 8 have been described previously.
Gene transfer efficiency in vitro
All cell lines were grown to 90% confluence in 60-mm Petri dishes. The cells of three dishes from each cell line were harvested by removal of the medium and addition of 0.25% versene, followed by 0.25% trypsin. After harvesting, 10% sera medium was added to the cell suspension for inactivation of the trypsin. The cells were counted with a hemocytometer, and the average number of cells per dish was calculated for each cell line.
Medium from the remaining dishes was replaced with 1 mL of serum-free medium. Control and treated cells were incubated with 0, 1, 10, and 100 particles/cell of AdZ.F(pK7), AdZ.F(RGD), and AdZ for 2 hours. Transfected dishes were rocked every 20 minutes for even distribution of the adenoviral vectors. The viral medium was then replaced with sera medium and incubated at 37°C for 24 hours.
Treated and control cells were trypsinized and harvested as described above. A suspension of 
Gene expression assay in vitro
Control and treated cells were incubated with 0, 1, 10, and 100 particles/cell of AdZ.F(pK7), AdZ.F(RGD), and AdZ for 2 hours in 1 mL of serum-free medium. Transfected dishes were rocked every 20 minutes for even distribution of the adenoviral vectors. The viral medium was then replaced with sera medium and incubated at 37°C for 24 hours. Cells were washed twice with sterile PBS (Sigma), and the ␤-gal activity of solubilized cells was measured in a luminometer by a chemiluminescent reporter assay (Galacto-Light Plus, Tropix, Bedford, Mass). Uninfected cells incubated with Galacton-Plus chemiluminescent substrate (Tropix) served as negative controls for ␤-gal activity. Negative control readings in relative light units (RLU) were subtracted from all transfected cell lines. The mean RLU and SEM for each treatment group were calculated from three individual experiments.
In vivo gene expression, biodistribution, and staining intensity
Glioma cells were grown to 90% confluence in 150-mm flasks. After harvesting with versene and trypsin as described above, the cells were washed three times with sterile PBS (Sigma) and counted with a hemocytometer. After centrifugation, 1 ϫ 10 7 U87, D54, and C6 glioma cells in 0.1 mL of PBS were injected subcutaneously via a 1-mL tuberculin syringe into the right hind limbs of athymic nude female mice (Fredrickson Cancer Research Institute, Boston, Mass). Syngeneic glioma tumors were induced using 1 ϫ 10 7 GL261 cells in 0.1 mL of PBS injected into the hind limbs of C57BL/6 mice (The Jackson Laboratory, Bar Harbor, Me). Tumor volumes were measured with vernier calipers and calculated biweekly from the following formula: (length ϫ width ϫ height/2), which is derived from the formula for an ellipsoid (d 3 /6). When the tumors reached an average size of 250 mm 3 , they were injected with 1 ϫ 10 7 and 1 ϫ 10 9 particles of AdZ.F(pK7), AdZ.F(RGD), or AdZ with a 10-L Hamilton syringe. Control tumors were not injected.
At 2 days postinjection, tumors were excised, placed in tubes, and quick-frozen in liquid nitrogen. Frozen tumors were then homogenized in 500 L of sodium chloride/tris(hydroxymethyl)aminomethane buffer (pH 7.5) containing ethylenediaminetetraacetic acid, dithiothreitol, and protease inhibitors. With a Brinkman Polytron, homogenates underwent four cycles of freezing in liquid nitrogen and thawing in a 37°C water bath. Samples were centrifuged for 5 minutes at 10,000 ϫ g, and the supernatant was measured for ␤-gal activity by means of a chemiluminescent reporter assay (Galacto-Light Plus, Tropix). Protein content was determined by the Bio-Rad Protein Micro Assay (Bio-Rad, Hercules, Calif). ␤-gal activity was reported as an average of RLU per micro-gram of protein, and the SEM was determined from three individual experiments.
The distribution of ␤-gal was determined from the excised tumors injected with AdZ.F(pK7), AdZ.F(RGD), or AdZ as described above. The tumors were then frozen-embedded in optimal cutting temperature compound (Miles, Elkhart, Ind) and cut into 10-m thick slices with a cryotome. ␤-gal expression was detected with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside histochemical stain. 16 The iodyl product was liberated from 5-bromo-4-chloro-3-indolyl ␤-D-galactoside by the catalytic activity of ␤-gal and was oxidized and self-coupled, forming an indigo blue derivative. Tumors were then imaged by light microscopy for the histologic pattern of blue-staining cells.
The intensity of ␤-gal staining was determined from the excised tumors injected with AdZ.F(pK7), AdZ.F(RGD), or AdZ as described above. The tumors were fixed in 10% neutral-buffered formalin, processed in a Tissue Tek II tissue processor (Miles), and embedded in paraffin. Sections of 5 m thickness were mounted, baked, cleared in xylene, and hydrated through a descending alcohol series and distilled water. Sections were stained with the fluorescein-di-␤-galactopyranoside (Sigma), and examined by ultraviolet microscopy using a Zeiss Photomicroscope III equipped with an epifluorescence condenser that converts photomicroscope to fluorescence microscope for incident-light excitation. Quantification of immunofluorescent ␤-gal staining was reported as mean and the SEM was determined at low power (ϫ40 magnification).
RESULTS
Frequency of gene expression in vitro
Transfection of human and rodent glioma cells with AdZ, AdZ.F(pK7), or AdZ.F(RGD) at low viral doses resulted in a variable frequency of ␤-gal gene expression (Fig 1) . All cell lines exhibited a dose-response relationship between viral dose (particles/cell) and the frequency of ␤-gal-positive cells. All cell lineages appeared to be transduced with all three vectors. In experiments, a frequency of 100% CMFDG-positive cells was observed at 100 particles/cell for all three vectors; therefore, we used lower doses to compare transduction efficiencies. The frequency of ␤-gal-positive cells declined at 48 and 72 hours posttransfection.
Exposure of U87 cells to AdZ.F(pK7) at 1 and 10 particles/cell resulted in expression of the ␤-gal gene in 68.6 -90% of the cells by fluorescence-activated cell sorting analysis. The frequencies of ␤-gal gene expression were lower for AdZ and lowest for AdZ.F(RGD). At 1 particle/cell, D54 cells showed equal frequencies of ␤-gal gene expression after transfection with each of the three vectors. D54 cells exposed to 10 particles/ cell resulted in a higher ␤-gal gene expression with AdZ.F(pK7) (71.9%), compared with AdZ (64.6%) and AdZ.F(RGD) (29.6%). GL261 cells transfected with AdZ.F(pK7) resulted in 66.8% and 93.2% of the cells expressing the ␤-gal gene at 1 and 10 particles/ cell, respectively. Exposure to AdZ or AdZ.F(RGD) resulted in similarly decreased frequencies of expression. Although there appeared to be a slight increase in the frequency of ␤-gal gene expression in C6 cells transfected with AdZ.F(pK7) compared with AdZ or AdZ.F(RGD), the SEM for these values were not significantly different.
Gene expression in vitro
The transduction efficiencies of the modified Ad vectors were compared in different glioma cell lines (Fig 2) . ␤-gal gene expression was determined 24 hours after increasing total particle doses of AdZ, AdZ.F(pK7), or AdZ.F(RGD) were incubated with the cells. All cell lines exhibited a dose-response relationship between viral dose (particles/cell) and the RLU of ␤-gal activity. Used as a positive control, A549 cells were transduced equally by all three vectors, indicating that the activity of the vector particles was not affected by the vector modifications.
In the glioma cell lines, the three vectors demonstrated different transduction levels. In both U87 and D54 cells, transfection with AdZ.F(pK7) resulted in a 2-to 3-fold increase in transduction over AdZ. AdZ.F(pK7) was ϳ20-fold more efficient and AdZ was ϳ4-fold more efficient than AdZ.F(RGD) in transducing U87 cells. In D54 cells, the transduction levels achieved by AdZ.F(RGD) were similar to those of AdZ. AdZ.F(pK7) transduced GL261 cells ϳ20-fold more efficiently than did AdZ. The transduction levels achieved by AdZ.F(RGD) were similar to those by AdZ in these cells. On average, AdZ.F(pK7) transduced C6 cells 2-fold more efficiently than did AdZ.F(RGD) and AdZ, but the SEM for these levels were not significantly different.
Gene expression in vivo
␤-gal gene expression was determined 2 days after 10 7 and 10 9 total particle doses of AdZ, AdZ.F(pK7), or AdZ.F(RGD) had been injected into glioma tumors. All tumors exhibited a dose-response relationship between viral dose (particles) and the RLU of ␤-gal activity (Fig  3) . AdZ.F(pK7) increased ␤-gal expression by 10-to 100-fold in U87, D54, GL261, and C6 tumors compared with AdZ. AdZ.F(RGD) increased ␤-gal expression by 10-fold in C6 tumors compared with AdZ.
Biodistribution of gene expression in vivo
The distribution of ␤-gal gene expression was determined 2 days after 10 7 and 10 9 total particle doses of AdZ, AdZ.F(pK7), or AdZ.F(RGD) had been injected into glioma tumors. Each tumor type exhibited immunohistochemical staining for ␤-gal in a similar pattern along the injection needle track (Fig 4) . The distance of ␤-gal staining from the needle track did not vary among vectors. When anti-␤-actin antibody staining was used as a control, there was no variation between transduced cells and adjacent cells with no ␤-gal expression. An increase in the number of transduced cells along the needle track was not observed.
Intensity of ␤-gal staining in vivo
The intensity of ␤-gal staining was determined 2 days after 10 7 and 10 9 total particle doses of AdZ, AdZ.F(pK7), or AdZ.F(RGD) were injected into glioma tumors. All cell lines exhibited immunofluorescent staining for ␤-gal along the injection needle track that corresponded to immunohistochemical staining. AdZ.F(pK7) exhibited an increased intensity of fluorescence compared with the other two vectors.
DISCUSSION
Ad vectors have been reported to transduce a variety of cell and tissue types. 3, 12, 17 Because of decreased adenoviral fiber expression in glioma cell lines, the reduced viral absorption results in diminished gene transfer efficiency. 10 In this study, we observed that a feasible approach to circumventing the limitation of these vectors was the alteration of the Ad fiber-coat proteins.
We used viral dosing of particles/cell to eliminate possible discrepancies in vector growth kinetics among the three vectors. 9 It has been reported that AdZ.F(pK7) makes smaller plaques than do unmodified vectors in plaque-forming unit (PFU) assays, and undetected plaques may obscure the particle-to-PFU ratio. In addition, AdZ.F(pK7) may aggregate in low salt concentrations, which would result in aberrant low PFU measurements (T. J. Wickham, unpublished data). We observed relatively consistent transduction among all three vectors when we used particles/cell to determine our gene transduction efficiency in vitro and in vivo.
We found that some malignant glioma cell cultures and tumors had improved transduction levels after exposure to a modified polylysine vector, AdZ.F(pK7), compared with an unmodified vector, AdZ. Polylysine has been shown to interact with heparan sulfate as well as other polyanions such as DNA, chondroitin sulfate, and mucins. 18, 19 Because these molecules are expressed on a variety of cell types, AdZ.F(pK7) acts as a nonspecific vector that can transduce a broad spectrum of tissues. 9 Because different glioma cell lines have been shown to express these ubiquitous cellular receptors, AdZ.F(pK7) may transduce an expanded range of glioma cell lines at higher efficiencies than do unmodified vectors. AdZ.F(pK7) may provide a broader therapeutic scope for different malignant gliomas in vitro and in vivo.
Fewer particles of AdZ.F(pK7) than of AdZ were necessary to transduce U87, D54, and GL261 cells in culture and U87, D54, GL261, and C6 tumors. Lower doses of therapeutic Ad have been shown to decrease the immune responses that frequently have been associated with Ad gene therapy. 10 -12 However, the Ad vector itself could produce a therapeutic effect. We also found that increasing the number of particles did not increase ␤-gal expression in all cell lines. One possible explanation for this finding is that the binding sites may be saturated in cell lines showing little increase in expression with increasing number of particles.
The improved transduction efficiency of AdZ.F(pK7) compared with AdZ and AdZ.F(RGD) that was demonstrated in vitro and in vivo did not correlate with the relatively similar patterns of viral biodistribution in vivo among all three vectors. This study and previous studies have shown the distribution of replication-deficient Ad to be restricted to a limited radius of cells along the intratumoral injection site. 20, 21 The limited exposure to glioma cells is due in part to intrinsic tumor pressure and to the nonreplicating feature of the vector, which inhibits viral diffusion. 21 The enhanced expression of ␤-gal by AdZ.F(pK7) compared with the other vectors results from an increased transduction efficiency of glioma cells along the injection site as demonstrated by an increased intensity of immunofluorescent ␤-gal staining.
The relative increase in ␤-gal expression with intratumoral AdZ.F(RGD) in C6 xenografts compared with measurements in vitro could be explained as the enhanced transduction efficiency of AdZ.F(RGD) in ex- posed tumor vasculature when compared with other vectors. 9, 10, 14, 15 However, AdZ.F(RGD) did not appear to improve transduction over AdZ in U87 and D54 xenografts or in GL261 tumors as had been observed in vitro. Vector binding to cells, whether glioma or endothelial cells, does not necessarily indicate that the vector will be internalized. 12 Further studies to distinguish between glioma and endothelial cell transduction should be considered for the characterization of transduction efficiencies in vivo.
Reduced transduction by AdZ vector may be an artifact due to a higher percentage of nonfunctional particles. Therefore, we compared PFU to particles and found a ratio of 1:1 for AdZ and AdZ.F(RGD), whereas pK7 had 1 PFU for every two particles. Moreover, we found that increased transduction by pK7 was cell type-specific. For example, increased transduction by pK7 is also cell type-specific in that C6 did not show increased expression (Fig 2) . Likewise, we found that RGD reduced transduction in all but one glioma type (C6). Finally, increased transduction by pK7 is eliminated by heparin. Therefore, it is unlikely that debris or nonfunctional AdZ particles results in artificially reduced transduction.
AdZ.F(pK7) improved the gene transfer efficiency of certain malignant glioma cell lines in culture and in tumors compared with the more commonly used AdZ. AdZ.F(pK7) may therefore be useful in gene therapy for targeting glioma cells that lack high levels of Ad fiber receptors but express a variety of polyanion cellular receptors. AdZ.F(RGD) demonstrated an increase in relative gene delivery to C6 glioma xenografts compared with cell culture, possibly as a result of ␣ integrin receptors on the tumor endothelium. This vector may be useful for the delivery of procoagulative or anti-angiogenetic proteins to endothelial cells in gliomas, because certain gene products diffuse out of transduced cells and function in a paracrine fashion. The observed increase in gene transduction by AdZ.F(pK7) and AdZ.F(RGD) may improve the efficacy of gene therapy for malignant gliomas.
